Prior treatment with oxaliplatin-containing regimens and higher total bilirubin levels are risk factors for neutropenia and febrile neutropenia in patients with gastric or esophagogastric junction cancer receiving weekly paclitaxel and ramucirumab therapy: a single center retrospective study
Abstract Background Weekly paclitaxel + ramucirumab (wPTX + RAM) therapy is recommended as the standard second-line chemotherapy regimen for unresectable advanced/recurrent gastric cancer (GC) or esophagogastric junction cancer. Recent subgroup analysis of the RAINBOW trial revealed a higher frequen...
Egile Nagusiak: | Katsuhiko Nara, Takehito Yamamoto, Hiroharu Yamashita, Koichi Yagi, Tappei Takada, Yasuyuki Seto, Hiroshi Suzuki |
---|---|
Formatua: | Artikulua |
Hizkuntza: | English |
Argitaratua: |
BMC
2023-10-01
|
Saila: | BMC Cancer |
Gaiak: | |
Sarrera elektronikoa: | https://doi.org/10.1186/s12885-023-11469-y |
Antzeko izenburuak
-
Prophylactic pegfilgrastim reduces febrile neutropenia in ramucirumab plus docetaxel after chemoimmunotherapy in advanced NSCLC: post hoc analysis from NEJ051
nork: Keita Miura, et al.
Argitaratua: (2024-02-01) -
Dose reduction of docetaxel avoids the usage of pegfilgrastim in docetaxel plus ramucirumab therapy for recurrent nonsmall cell lung cancer
nork: Kosuke Hamai, et al.
Argitaratua: (2023-04-01) -
How I treat febrile neutropenia
nork: Marcio Nucci
Argitaratua: (2021-02-01) -
Prediction of esophagogastric varices associated with oxaliplatin administration
nork: Yosuke Satta, et al.
Argitaratua: (2021-11-01) -
La neutropenia
nork: Efraín Pulla Cadmilema, et al.
Argitaratua: (2023-08-01)